Salvage Therapy With a Triple Combination of Daptomycin,Carbapenem,and Oxazolidinone in Patients With Persistent MRSA Bacteremia of Cardiovascular Focus: A Case Series

Abstract

Get full access to this article

View all access options for this article.

References

Hawkins

Huang

Jin

Noskin

Zembower

Bolon

Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med. 2007;167(17):1861-1867. doi:10.1001/archinte.167.17.1861

Rose

Fantl

Geriak

Nizet

Sakoulas

Current paradigms of combination therapy in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: does it work, which combination, and for which patients?

Clin Infect Dis. 2021;73(12):2353-2360. doi:10.1093/cid/ciab452

Minejima

Mai

Bui

, et al Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020;70(4):566-573. doi:10.1093/cid/ciz257

McCreary

Kullar

Geriak

, et al Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis. 2020;7(1):ofz538. doi:10.1093/ofid/ofz538

Samura

Takada

Hirose

, et al Comparison of the efficacy and safety of standard- and high-dose daptomycin: a systematic review and meta-analysis. Br J Clin Pharmacol. 2023;89(4):1291-1303. doi:10.1111/bcp.15671